Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering 12.15.21 Syndax Announces Proposed Public Offering of Common Stock 12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease 12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab 11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update 11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting 09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases 09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors 09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences 08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
